| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(90)93187-T |
| P698 | PubMed publication ID | 1979100 |
| P50 | author | Hugh R. Taylor | Q37393483 |
| P2093 | author name string | B M Greene | |
| B Muñoz | |||
| G Poetschke | |||
| J Foose | |||
| M Pacqué | |||
| P433 | issue | 8729 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pregnancy outcome | Q66057507 |
| ivermectin | Q415178 | ||
| P304 | page(s) | 1486-1489 | |
| P577 | publication date | 1990-12-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution | |
| P478 | volume | 336 |
| Q92869595 | A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool |
| Q41454208 | Anthelmintics. A comparative review of their clinical pharmacology |
| Q33815900 | Before using ivermectin therapy for scabies |
| Q97570175 | Chemotherapy in the treatment, control, and elimination of human onchocerciasis |
| Q33455448 | Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition |
| Q36711722 | Dermatologic treatment during pregnancy: practical overview |
| Q35743788 | Impact of ivermectin on illness and disability associated with onchocerciasis |
| Q35594646 | Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis |
| Q33593852 | Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety |
| Q36858823 | Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination |
| Q44800580 | Ivermectin use in tropical medicine |
| Q36711492 | Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis |
| Q50637048 | Missed treatment opportunities, for pregnant and breast-feeding women, in onchocerciasis mass-treatment programmes in south-eastern Nigeria. |
| Q35669731 | Parasitic infections in women and their consequences |
| Q34724394 | Pesticide exposures and developmental outcomes: the epidemiological evidence |
| Q52186757 | Pesticide exposures and fetal death: a review of the epidemiologic literature. |
| Q24170108 | Pesticides and hypospadias: a meta-analysis |
| Q37509865 | Pharmacologic advances in canine and feline reproduction |
| Q38217356 | Present-day anthelmintics and perspectives on future new targets. |
| Q33614784 | Pulmonary Strongyloidiasis: The Varied Clinical Presentations |
| Q28076817 | Safety of Topical Medications for Scabies and Lice in Pregnancy |
| Q91989091 | Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis |
| Q35930608 | Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer |
| Q56066171 | Sushi in Pregnancy, Parasitic Diseases - Obstetrician Survey |
| Q57115115 | The Skin-A Common Pathway for Integrating Diagnosis and Management of NTDs |
| Q50477407 | The elimination of scabies: a task for our generation. |
| Q74766273 | The pregnant traveler |
| Q92614344 | The public health control of scabies: priorities for research and action |
| Q34880355 | The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. |
| Q36066068 | Treatment strategies underpinning the global programme to eliminate lymphatic filariasis |
| Q57951603 | Tropical medicine |
| Q45023010 | [Ivermectin] |
Search more.